We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Silicon Chip Based Blood Test Rapidly Diagnoses Patients with Hypothyroidism

By HospiMedica International staff writers
Posted on 29 Jul 2024
Print article
Image: The Maverick system’s silicon chip technology is poised to revolutionize lab care (Photo courtesy of Genalyte)
Image: The Maverick system’s silicon chip technology is poised to revolutionize lab care (Photo courtesy of Genalyte)

Hypothyroidism impacts about 10% of the U.S. population, making the Thyroid Stimulating Hormone (TSH) test the most frequently conducted immunoassay in the United States. Traditional testing often involves significant time commitments for patients, including visits to labs and waiting 2 to 5 days for results. Now, a new TSH immunoassay performed on a silicon chip delivers results in approximately 30 minutes.

Genalyte (San Diego, CA, USA) has received U.S. Food and Drug Administration (FDA) approval for its groundbreaking immunoassay, the first of its kind to be cleared for use on a silicon chip-based device. The Maverick Diagnostic System (MDS) incorporates silicon chip-based photonic ring resonator technology, enabling the execution of multiple rapid tests simultaneously from a small sample of whole blood or serum. This system is also connected to the cloud, facilitating the retrieval of assay protocols and enabling clinical oversight. Genalyte’s innovation effectively minimizes the traditional bulky lab machinery to 3% of its original size while still delivering lab-quality results.

The compact Maverick Diagnostic System, comparable in size to a small microwave and weighing just 30 pounds, offers lab-quality results on-site, representing a significant shift in laboratory processing much like the transformation brought by silicon chips in computing. This technology promises to significantly reduce the turnaround time for lab results by 98%, potentially making it available at point-of-care locations in the future. This FDA clearance not only marks a critical achievement for Genalyte but also for the diagnostic industry, confirming the company’s capability to deliver precise and rapid lab results.

“This TSH assay is a powerful tool to rapidly diagnose patients and get them on a path to treatment quicker,” said CEO of Genalyte Ashraf Hanna, Ph.D., M.D. “This technology is groundbreaking for immunoassay development which hasn’t changed conceptually since 1959. The Maverick has the potential to allow a broad menu of blood testing in a small, portable device at the point of care.”

Related Links:
Genalyte

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Vacuum-Assisted Breast Biopsy Device
Celero
New
Suction Electrode System
Strässle

Print article

Channels

Critical Care

view channel
Image: The Atmo Gas Capsule measures gases as it travels through the GI tract and transmits the data wirelessly (Photo courtesy of Atmo Biosciences)

Ingestible Smart Capsule for Chemical Sensing in the Gut Moves Closer to Market

Intestinal gases are associated with several health conditions, including colon cancer, irritable bowel syndrome, and inflammatory bowel disease, and they have the potential to serve as crucial biomarkers... Read more

Surgical Techniques

view channel
Image: Intravascular imaging can improve outcomes for complex stenting procedures in patients with high-risk calcified coronary artery disease (Photo courtesy of Shutterstock)

Intravascular Imaging for Guiding Stent Implantation Ensures Safer Stenting Procedures

Patients diagnosed with coronary artery disease, which is caused by plaque accumulation within the arteries leading to chest pain, shortness of breath, and potential heart attacks, frequently undergo percutaneous... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more